SOPHiA GENETICS and Agilent Partner on Comprehensive Solution for Cancer Analysis
March 14 2023 - 9:00AM
Business Wire
Collaboration provides a solution for a more
in-depth analysis of cancer biomarkers
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company
in the healthcare space and the leader in data-driven medicine, is
partnering with Agilent to offer a comprehensive solution for
cancer analysis.
Through the partnership, the SOPHiA DDMTM Platform will be
integrated with Agilent’s new Research Use Only SureSelect Cancer
Comprehensive Genomic Profiling (CGP) Assay Kit. This will enable
clinical researchers to accurately identify multiple biomarkers,
lowering the risk of missing important information in cancer
samples. The partnership brings together these two companies’
strengths in analytics and next generation sequencing (NGS) assay
development to facilitate novel approaches to cancer research.
“Working with Agilent means combining best-in-class profiling
practices with rich data and insights,” said Kevin Puylaert, Vice
President, Business Development & Marketing, SOPHiA GENETICS.
“Together, we can break traditional barriers that often limit new
discoveries, democratizing access to data-driven medicine around
the world.”
SOPHiA GENETICS is tailoring its analytics to work in harmony
with Agilent’s target enrichment technology so that users have
access to an advanced solution that allows multiple tumor markers
to be detected. With the SOPHiA DDMTM Platform, users will have an
integrated solution with reporting tools that go beyond simple
readouts, aligned with the information and input from the latest
guidelines and clinical trials reflecting relevant biomarkers.
“We chose to partner with SOPHiA GENETICS to leverage their
analytical and reporting capabilities, which complements our
SureSelect Cancer CGP panel, to drive toward providing clinical
researchers with a complete set of tools that will make
comprehensive tumor profiling possible in their own labs,” said
Kevin Meldrum, Vice President and General Manager, Integrated
Genomics Division, Agilent Technologies.
The combined efforts of Agilent and SOPHiA GENETICS will make it
possible for labs of varying sizes to bring cancer analysis
in-house without having to send out samples or output data to other
vendors and labs. This keeps impactful bioinformatic information in
the hands of the user for future reference or research.
TomaLab, one of the largest research and genetics laboratories
in Italy, is participating in an early-access program that is
currently underway.
“Our laboratory is excited by the Agilent and SOPHiA GENETICS
partnership and the release of their integrated CGP solution,” said
Vittorio Grazioli, CEO of TomaLab. “Combining high-quality
reagents, automation options, and powerful analytics into one
unique workflow will help us maximize insights from CGP data while
improving our efficiency."
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated
to establishing the practice of data-driven medicine as the
standard of care and for life sciences research. It is the creator
of the SOPHiA DDM™ Platform, a cloud-native platform capable of
analyzing data and generating insights from complex multimodal data
sets and different diagnostic modalities. The SOPHiA DDM™ Platform
and related solutions, products and services are currently used by
a broad network of hospital, laboratory, and biopharma institutions
globally. For more information, visit SOPHiAGENETICS.COM, or
connect on Twitter, LinkedIn, Facebook, and Instagram.
Where others see data, we see answers.
SOPHiA GENETICS products are for Research Use Only and not for
use in diagnostic procedures, unless specified otherwise. The
information in this press release is about products that may or may
not be available in different countries and, if applicable, may or
may not have received approval or market clearance by a
governmental regulatory body for different indications for use.
Please contact support@sophiagenetics.com to obtain the appropriate
product information for your country of residence.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute
forward-looking statements. All statements other than statements of
historical facts contained in this press release, including
statements regarding our future results of operations and financial
position, business strategy, products and technology, as well as
plans and objectives of management for future operations, are
forward-looking statements. Forward-looking statements are based on
our management’s beliefs and assumptions and on information
currently available to our management. Such statements are subject
to risks and uncertainties, and actual results may differ
materially from those expressed or implied in the forward-looking
statements due to various factors, including those described in our
filings with the U.S. Securities and Exchange Commission. No
assurance can be given that such future results will be achieved.
Such forward-looking statements contained in this press release
speak only as of the date hereof. We expressly disclaim any
obligation or undertaking to update these forward-looking
statements contained in this press release to reflect any change in
our expectations or any change in events, conditions, or
circumstances on which such statements are based, unless required
to do so by applicable law. No representations or warranties
(expressed or implied) are made about the accuracy of any such
forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230314005541/en/
Media: Nick Puleo npuleo@comsint.com
Sophia Genetics (NASDAQ:SOPH)
Historical Stock Chart
From May 2024 to Jun 2024
Sophia Genetics (NASDAQ:SOPH)
Historical Stock Chart
From Jun 2023 to Jun 2024